A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days

OBJECTIVE: To assess the safety of VivaGel® used vaginally twice daily for 14 days among healthy, sexually-abstinent women, aged 18–24 years in the USA and Kenya. DESIGN: Randomized placebo controlled trial. METHODS: Participants were randomized 2∶1, VivaGel to placebo. Safety was assessed by compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Craig R., Brown, Joelle, Moscicki, Anna-Barbara, Bukusi, Elizabeth A., Paull, Jeremy R. A., Price, Clare F., Shiboski, Stephen
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024437/
https://www.ncbi.nlm.nih.gov/pubmed/21311578
http://dx.doi.org/10.1371/journal.pone.0016258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024437/
https://www.ncbi.nlm.nih.gov/pubmed/21311578
http://dx.doi.org/10.1371/journal.pone.0016258

Ejemplares similares